IL17A and systemic lupus erythematosus: IL-17 has not been therapeutically targeted in SLE patients to date, but data from recent clinical trials in other inflammatory autoimmune diseases such as and Crohn's disease can partially inform us about the efficacy and safety of blocking IL-17 either directly or indirectly by targeting IL-23 in SLE patients [145].